Analystreport

Syros Pharmaceuticals Inc (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at Cann. They now have a $26.00 price target on the stock.

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com